The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Phase Ib Trial of Mutant Herpes Simplex Virus G207 Inoculated Pre-and Post-tumor Resection for Recurrent GBM
Open accessAbstract
We have previously demonstrated safety of G207, a doubly mutated (deletion of both gamma(1)34.5 loci, insertional inactivation of U(L)39) herpes simplex virus (HSV) for patients stereotactically inoculated in enhancing portions of recurrent malignant gliomas. We have now determined safety of two inoculations of G207, before and after tumor resection. Inclusion criteria were histologically proven recurrent malignant glioma, Karnofsky score >or=70, and ability to resect the tumor without ventricular system breach. Patients received two doses of G207 totaling 1.15 x 10(9) plaque-forming units with 13% of this total injected via a catheter placed stereotactically in the tumor. Two or five days later, tumor was resected en bloc with catheter in place. The balance of G207 dose was injected into brain surrounding the resection cavity. Six patients with recurrent glioblastoma multiforme were enrolled. Two days after the second G207 inoculation, one patient experienced transient fever, delirium, and hemiparesis, which entirely resolved on high-dose dexamethasone. No patient developed HSV encephalitis or required treatment with acyclovir. Radiographic and neuropathologic evidence suggestive of antitumor activity is reported. Evidence of viral replication was demonstrated. G207 appears safe for multiple dose delivery, including direct inoculation into the brain surrounding tumor resection cavity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
Walker, M. D., Green, S. B., Byar, D. P., Alexander, E., Batzdorf, U., Brooks, W. H., Hunt, W. E., MacCarty, C. S., Mahaley, M. S., Mealey, J., et al. (1980) · New England Journal of Medicine · doi:10.1056/nejm198012043032303 · Cited by 1,611
Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant
Martuza, R. L., Malick, A., Markert, J. M., Ruffner, K. L., & Coen, D. M. (1991) · Science · doi:10.1126/science.1851332 · Cited by 1,050
Self-citationMarkert, J. M., Medlock, M. D., Rabkin, S. D., Gillespie, G. Y., Todo, T., Hunter, W. D., Palmer, C. A., Feigenbaum, F., Tornatore, C., Tufaro, F., et al. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301205 · Cited by 976
Self-citationAttenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas
Mineta, T., Rabkin, S. D., Yazaki, T., Hunter, W. D., & Martuza, R. L. (1995) · Nature Medicine · doi:10.1038/nm0995-938 · Cited by 822
Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells
Ram, Z., Culver, K. W., Oshiro, E. M., Viola, J. J., DeVroom, H. L., Otto, E., Long, Z., Chiang, Y., McGarrity, G. J., Muul, L. M., et al. (1997) · Nature Medicine · doi:10.1038/nm1297-1354 · Cited by 668
Chiocca, E. A., Abbed, K. M., Tatter, S., Louis, D. N., Hochberg, F. H., Barker, F., Kracher, J., Grossman, S. A., Fisher, J. D., Carson, K., et al. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.07.021 · Cited by 436
Self-citationCyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses
Fulci, G., Breymann, L., Gianni, D., Kurozomi, K., Rhee, S. S., Yu, J., Kaur, B., Louis, D. N., Weissleder, R., Caligiuri, M. A., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605496103 · Cited by 357
Harrow, S., Papanastassiou, V, Harland, J., Mabbs, R., Petty, R., Fraser, M., Hadley, D., Patterson, J., Brown, S. M., & Rampling, R. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302289 · Cited by 342
Parker, J. N., Gillespie, G. Y., Love, C. E., Randall, S., Whitley, R. J., & Markert, J. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.040557897 · Cited by 332
Self-citationDevelopment of multiple lesions during radiation therapy and chemotherapy in patients with gliomas
Choucair, A. K., Levin, V. A., Gutin, P. H., Davis, R. L., Silver, P., Edwards, M. S. B., & Wilson, C. B. (1986) · Journal of Neurosurgery · doi:10.3171/jns.1986.65.5.0654 · Cited by 255
Hunter, W. D., Martuza, R. L., Feigenbaum, F., Todo, T., Mineta, T., Yazaki, T., Toda, M., Newsome, J. T., Platenberg, R. C., Manz, H. J., et al. (1999) · Journal of Virology · doi:10.1128/jvi.73.8.6319-6326.1999 · Cited by 191
Markert, J. M., Malick, A., Coen, D. M., & Martuza, R. L. (1993) · Neurosurgery · doi:10.1097/00006123-199304000-00016 · Cited by 187
Self-citationToda, M., Martuza, R. L., Kojima, H., & Rabkin, S. D. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.9.4457 · Cited by 161
Effect of Chemotherapy-Induced DNA Repair on Oncolytic Herpes Simplex Viral Replication
Aghi, M. K., Rabkin, S. D., & Martuza, R. L. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj003 · Cited by 145
Attenuated, Replication-Competent Herpes Simplex Virus Type 1 Mutant G207: Safety Evaluation in Mice
Sundaresan, P., Hunter, W. D. G., Martuza, R. L., & Rabkin, S. D. (2000) · Journal of Virology · doi:10.1128/jvi.74.8.3832-3841.2000 · Cited by 140
Highly anaplastic astrocytoma: A review of 357 patients treated between 1977 and 1989
Prados, M. D., Gutin, P. H., Phillips, T. L., et al. (1992) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(92)90537-r · Cited by 116
Harsh, G. R., Deisboeck, T. S., Louis, D. N., et al. (2000) · Journal of neurosurgery · doi:10.3171/jns.2000.92.5.0804 · Cited by 109
Genetically engineered HSV in the treatment of glioma: a review
Markert, J. M., Gillespie, G. Y., Weichselbaum, R. R., Roizman, B., & Whitley, R. J. (2000) · Reviews in Medical Virology · Cited by 84
Self-citationSalvage Chemotherapy With Tamoxifen for Recurrent Anaplastic Astrocytomas
Chamberlain, M. C., & Kormanik, P. A. (1999) · Archives of Neurology · doi:10.1001/archneur.56.6.703 · Cited by 70
Bünzli, D., Wietlisbach, V., Barazzoni, F., Sahli, R., & Meylan, P. R. (2004) · BMC Infectious Diseases · doi:10.1186/1471-2334-4-10 · Cited by 53
Seroprevalence of herpes simplex virus types 1 and type 2 in the Frankfurt am Main area, Germany
Rabenau, H. F., Buxbaum, S., Preiser, W., et al. (2001) · Medical Microbiology and Immunology · doi:10.1007/s00430-001-0102-1 · Cited by 50
Salvage Chemotherapy with Taxol for Recurrent Anaplastic Astrocytomas
Chamberlain, M. C., & Kormanik, P. A. (1999) · Journal of Neuro-Oncology · doi:10.1023/a:1006277631745 · Cited by 42
Hashido, M., Kawana, T., Matsunaga, Y., & Inouye, S. (1999) · Microbiology and Immunology · doi:10.1111/j.1348-0421.1999.tb02390.x · Cited by 41
Standard treatment and experimental targeted drug therapy for recurrent glioblastoma multiforme.
Sm, C., Na, B., Pk, S., & Garner (2006) · PubMed · Cited by 31
Temozolomide Chemotherapy in Patients with Recurrent Malignant Gliomas
Yang, S.-H., Kim, M.-K., Lee, T., Lee, K., Jeun, S.-S., Park, C.-K., Kang, J.-K., Kim, M., & Hong, Y.-K. (2006) · Journal of Korean Medical Science · doi:10.3346/jkms.2006.21.4.739 · Cited by 18
Cited by
Whitley, R. J., & Roizman, B. (2002) · Wiley Encyclopedia of Molecular Medicine · doi:10.1002/0471203076.emm0597 · Cited by 700
Self-citationExosomes from marrow stromal cells expressing miR-146b inhibit glioma growth
Katakowski, M., Buller, B., Zheng, X., Lu, Y., Rogers, T., Osobamiro, O., Shu, W., Jiang, F., & Chopp, M. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.02.019 · Cited by 681
Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial
Todo, T., Ito, H., Ino, Y., Ohtsu, H., Ota, Y., Shibahara, J., & Tanaka, M. (2022) · Nature Medicine · doi:10.1038/s41591-022-01897-x · Cited by 526
Emerging therapies for glioblastoma: current state and future directions
Rong, L., Li, N., & Zhang, Z. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02349-7 · Cited by 510
Lundstrom, K. (2018) · Diseases · doi:10.3390/diseases6020042 · Cited by 469
Metadata
- Authors
- Markert, J. M., Liechty, P. G., Wang, W., Gaston, S., Braz, E., Karrasch, M., Nabors, L. B., Markiewicz, M., Lakeman, A. D., Palmer, C. A., Parker, J. N., Whitley, R. J., & Gillespie, G. Y.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2009-01
- Volume
- 17
- Issue
- 1
- Pages
- 199-207
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2094949672
- Cited by
- 401
- References
- 27
- FWCI
- 11.95
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.